Redefining the phenotype of ALSP and AARS2 mutation–related leukodystrophy
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 5, 2016
- Accepted in final form January 4, 2017
- First Published February 15, 2017.
Author Disclosures
- Rahul Lakshmanan, FRANZCR,
- Matthew E. Adams, FRCR,
- David S. Lynch, MRCPI,
- Justin A. Kinsella, MRCPI,
- Rahul Phadke, FRCPath,
- Jonathan M. Schott, FRCP,
- Elaine Murphy, MRCP,
- Jonathan D. Rohrer, MRCP,
- Jeremy Chataway, FRCP,
- Henry Houlden, FRCP,
- Nick C. Fox, FRCP and
- Indran Davagnanam, FRCR
- Rahul Lakshmanan, FRANZCR,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Matthew E. Adams, FRCR,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Lynch, MRCPI,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Justin A. Kinsella, MRCPI,
NONE
NONE
Funding from Novartis for attendance at the American Academy of Neurology Meeting 2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Dr. Kinsella was previously funded by the Stanley Thomas Johnson Foundation, Bayer Schering Ireland, Pfizer Ireland and Elitech UK.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Rahul Phadke, FRCPath,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan M. Schott, FRCP,
Scientific advisory board for Eli Lilly and Roche Data Safety Monitoring Board for Axon Neuroscience
NONE
Travel and speaker honoraria from (1) the US Alzheimer's Association; (2) European Academy of Neurology; (3) Association of British Neurologists
NONE
NONE
The Clinical Syndrome of Alzheimer's disease, Henry Stewart Talks, 2016
NONE
(1) Elil Lilly, (2) Roche
NONE
NONE
NONE
I have received funding for research studies from Eli Lilly
NONE
(1) Alzheimer's Research UK, (2) UK Alzheimer's Society, (3) EPSRC, (4) Medical Research Council, (5) EU, Horizon 20:20, (6) Wolfson Foundation, (7) Wellcome Trust, (8) Brain Research Trust
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Elaine Murphy, MRCP,
NONE
NONE
1) Vitaflo International, Honorarium for lecture 2) Shire HGT, unrestricted educational grant 3) Genzyme Inc., Unrestricted educational grant 4) Nutricia, Honaria for lectures
Orphanet Journal of Rare Disease https://ojrd.biomedcentral.com/ Section Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1) Shire HGT, unrestricted educational grant 2) Genzyme Inc., Unrestricted educational grant 3) Nutricia, educational grant
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonathan D. Rohrer, MRCP,
Medical advisory board for Ionis Pharmaceuticals.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
MRC Clinician Scientist Fellowship, MR/M008525/1.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jeremy Chataway, FRCP,
1)Roche Merck
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1)Novartis
1)MRC-EME, 11/30/11, CI, 2013-2018
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Henry Houlden, FRCP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
My laboratory is funded by: The Medical Research Council (MRC) UK, The BRT, The MDA USA, Muscular Dystrophy UK, Rosetrees Trust, The Wellcome Trust and the National Institute for Health (NIHR) UCL/UCLH BRC. Research (NIHR) UCLH/UCL Biomedical Research Centre.
NONE
My laboratory is funded by: The Dystonia Medical Research Foundation (DMRF), The Parkinson's Disease Foundation (PDF), National Organisation for Rare Disorders (NORD) and The Brain Research Trust (BRT). The National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre.
NONE
NONE
NONE
NONE
NONE
NONE
- Nick C. Fox, FRCP and
Payments were made to University College London (1)Biogen
NONE
NONE
(1) Alzheimer's Disease and Associated Disorders, Editorial Board Member, 2004 to present; No compensation (2) Neurodegenerative Diseases, Editorial Board Member, 2004 to present; No compensation (3) Alzheimer?s Research and Therapy, Editorial Board Member, 2008 to present; No compensation (4) Lancet Neurology, Editorial Board Member, 2014 to present; No compensation
(1) QA Box for automated checking of MRI scans; Filed 4 May 2007
(1) Neuroimaging in Dementia, Springer, 2011
NONE
Payments were made to University College London. (1) Janssen (2) Roche/Genentech (3)Eli Lilly (4) Novartis Pharma AG (5) Sanofi (6) GSK (7) Biogen
NONE
NONE
NONE
Payments were made to the Dementia Research Centre, UCL (no personal compensation to me) for A. Image analyses for: (1) Janssen Alzheimer's Immunotherapy (2) Wyeth B. My Institution also received payment for my participation on advisory boards for (1) Novartis, 2015 (2) Eli Lilly, 2015 (3) Genentech/Roche, 2014 (4) GSK, 2015 (5) Biogen, 2016 - for DMC participation All payments were made to my Institution (University College London) and although I did not receive personal compensation these payments benefited my research group.
(1) MRC (UK), [Grant G0801306], PI, 2009-14; (2) NIA, Grant [U01 AG024904], Co-I, 2005-2014; (3) NIHR, Senior Investigator Award, 2009-present (3) NIHR, Queen Square Biomedical Research Unit in Dementia, 2012-present
NONE
(1) Wolfson Foundation, funding for the Leonard Wolfson Experimental Neurology Centre
NONE
NONE
NONE
NONE
NONE
NONE
- Indran Davagnanam, FRCR
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institute of Health Research UCL/UCLH Biomedical Research Centre funding for one consultant session since 2013.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Lysholm Department of Neuroradiology (R.L., M.E.A., I.D.), the National Hospital for Neurology and Neurosurgery; Department of Molecular Neuroscience (D.S.L., H.H.), UCL Institute of Neurology; the Leonard Wolfson Experimental Neurology Centre (D.S.L., J.A.K.), the National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology; Dementia Research Centre (J.A.K., J.M.S., J.D.R., N.C.F.), Department of Neurodegeneration, UCL Institute of Neurology, UK; Department of Neurology (J.A.K.), St Vincent's University Hospital, University College Dublin, Ireland; Division of Neuropathology and Department of Neurodegenerative Disease (R.P.), Charles Dent Metabolic Unit (E.M.), Department of Neuroinflammation (J.C.), Neurogenetics Laboratory (H.H.), and Department of Brain Repair and Rehabilitation (I.D.), the National Hospital for Neurology and Neurosurgery, UCL Institute of Neurology, UK.
- Correspondence to Dr. Davagnanam: i.davagnanam{at}ucl.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang
► Watch
Related Articles
- No related articles found.